DB18387ExperimentalProtein Based Therapies
GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
- Mechanism
- Curator reviewed
Pharmacologically active on Interleukin-13 receptor subunit alpha-2
- Code names
- GB-13
Resolves to
Targets
What you can answer from here — as of July 09, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with GB-13, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account